31.2 C
New York
Thursday, July 3, 2025

Tag: Taxation

newssourcecompanyFORcontentinformation1marketbusiness

Minsud Announces Closing of Over-Subscribed Private Placement

/THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN...

/R E P E A T — Collective Mining Drills 534 g/t Gold & 40 g/t Silver Over 0.65 Metres at the ME Target...

A new high-grade vein system has been discovered in hole MEC-2 at the ME target (located southeast of Apollo) with assay results as follows:0.65...

Trump’s Fiscal Fireworks: A Brilliant Plan for Economic Chaos

Ah, Washington. The paragon of fiscal prudence. For decades, our esteemed lawmakers have been engaged in a bipartisan race to see who can degrade...

EZGO ANNOUNCES FINANCIAL RESULTS FOR THE SIX MONTHS ENDED MARCH 31, 2025

CHANGZHOU, China, July 1, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions...

Collective Mining Drills 534 g/t Gold & 40 g/t Silver Over 0.65 Metres at the ME Target and Commences Drilling on Multiple Apollo Look-alike...

A new high-grade vein system has been discovered in hole MEC-2 at the ME target (located southeast of Apollo) with assay results as follows:0.65...

Arizona Metals Announces 2025 Mineral Resource Estimate for Kay Mine Project

/NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR...

Ninepoint Partners Announces Final June 2025 Cash Distribution for Ninepoint Cash Management Fund – ETF Series

TORONTO, June 27, 2025 (GLOBE NEWSWIRE) -- Ninepoint Partners LP (“Ninepoint Partners”) today announced the final June 2025 cash distribution for the Ninepoint Cash Management Fund - ETF Series. The record date for the distribution is June 30, 2025. This distribution is payable on July 8, 2025.

Collective Mining Discovers a New Copper-Silver Rich Sub-Zone in Apollo, Intersecting 114.40 metres at 4.14 g/t Gold Equivalent

A new high–grade sub-zone ("HZ2"), enriched in copper and silver, has been discovered in the Apollo system. HZ2, which remains open for expansion, is...

Ninepoint Partners Announces June 2025 Cash Distributions for ETF Series Securities

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- Ninepoint Partners LP (“Ninepoint Partners”) today announced the June 2025 cash distributions for its ETF Series securities. The record date for the distributions is June 30, 2025. All distributions are payable on July 8, 2025.

Collective Mining Earns 100% in the Guayabales Mining License by Accelerating the Terms of the Agreement

TORONTO, June 23, 2025 /CNW/ - Collective Mining Ltd. (NYSE: CNL) (TSX: CNL) ("Collective" or the "Company") is pleased to announce that it has...

The Inner Circle acknowledges, Dr. R. LeWayne Johnson, PhD, LLM, JD, MBA as a Pinnacle Professional Member

KISSIMMEE, Fla., June 20, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. R. LeWayne Johnson, PhD, LLM, JD, MBA is acknowledged as...

Johnson Pope Expands Legal Talent with the Addition of Jessica Warwick and Samuel C. Craig to Its St. Petersburg Office

ST. PETERSBURG, Fla., June 20, 2025 /PRNewswire/ -- Johnson, Pope, Bokor, Ruppel & Burns, LLP is proud to announce the addition of two new associate...

Senate Republicans Tinker with Taxes—Because That Always Solves Everything

Senate Republicans are at it again, having emerged from their smoke-filled rooms with a fresh batch of tax proposals set to tickle the fancy...

Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia

CAMBRIDGE, Mass., June 18, 2025 (GLOBE NEWSWIRE) --  Biogen Inc. (Nasdaq: BIIB) announced the initiation of dosing in the BRAVE study, a global Phase 3 clinical trial. The BRAVE study will evaluate the efficacy and safety of omaveloxolone in children with Friedreich ataxia (FA) between the ages of 2 to <16. Both non-ambulatory and ambulatory participants may qualify for the study. Participants will be randomized 2:1 to receive omaveloxolone or placebo once a day for 52 weeks before having the opportunity to move into the open-label extension (OLE). Currently, omaveloxolone is commercialized under the brand name SKYCLARYS® in over 40 countries, including in the U.S. and the European Union, and is the only approved product for FA in adults and adolescents aged 16 years and older.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTaxation

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers